Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | PKM | P14618 | 1/20 | 0.33 |
| ▸ | BACE1 | P56817 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6062480 | 0.94 | BACE1 (0.32) | KDM4EPKMBACE1 | |
| SCHEMBL1730371 | 0.89 | KDM4E (0.32) | KDM4EPKMBACE1 | |
| SCHEMBL6062481 | 0.88 | DPP4 (0.39) | — | |
| SCHEMBL6062485 | 0.88 | DPP4 (0.39) | — | |
| SCHEMBL1729947 | 0.87 | BACE1 (0.31) | BACE1 | |
| SCHEMBL1728231 | 0.87 | KEAP1 (0.31) | KDM4EPKMBACE1 | |
| SCHEMBL6063359 | 0.77 | TOP2A (0.32) | — | |
| SCHEMBL6063059 | 0.77 | TOP2A (0.32) | — | |
| SCHEMBL6062512 | 0.77 | DPP8 (0.32) | — | |
| SCHEMBL1728234 | 0.76 | KEAP1 (0.30) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1651653-B1 | NOVEL CYANO THIAZOLIDES, METHODS FOR THE PRODUCTION THEREOF, AND USE THEREOF AS A MEDICAMENT | SANOFI AVENTIS DEUTSCHLAND (DE) | 2011-11-23 | — | — | EP | disclosed |
| EP-1720856-A2 | HIV INTEGRASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2006-11-15 | — | — | EP | disclosed |
| US-7008957-B2 | Bicyclic cyanoheterocycles, process for their preparation and their use as medicaments | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2006-03-07 | — | — | US | disclosed |
| WO-2005077050-A2 | HIV INTEGRASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2005-08-25 | — | — | WO | disclosed |
| US-20050059716-A1 | Novel bicyclic cyanoheterocycles, process for their preparation and their use as medicaments | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2005-03-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050059716-A1 | Novel bicyclic cyanoheterocycles, process for their preparation and their use as medicaments | CYP11B2, GOT2, CYP11B1 | KDM4E 2831/4885PKM 777/4885BACE1 1555/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.